According to the Zhitong Finance App, Gacos-B (01167.HK) announced that the first phase IB/III clinical trial of the company's pan-KRAS inhibitor jab-23e73 combined with albumin-binding paclitaxel and gemcitabine for first-line treatment of KRAS mutant pancreatic cancer was completed in China.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.